2,3-二氢苯并[b]呋喃-7-胺 | 13414-56-7

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 2,3-二氢苯并[b]呋喃-7-胺
• 中文别名: 2,3-二氢苯并呋喃-7-胺；7-氨基-2,3-二氢苯并呋喃
• 英文名称: 2,3-dihydrobenzofuran-7-amine
• 英文别名: 2,3-dihydro-1-benzofuran-7-amine；2,3-dihydro-7-benzofuranamine；2,3-dihydrobenzo[b]furan-7-ylamine
• CAS: 13414-56-7
• 化学式: C₈H₉NO
• mdl: MFCD11109313
• 分子量: 135.166
• InChiKey: UHHZGSLXPQGPJL-UHFFFAOYSA-N

物化性质

• 沸点：
  60 °C(Press: 0.1 Torr)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存储条件：2-8°C，避免光照，密封保存。

反应信息

• 作为反应物：
  描述：

  2,3-二氢苯并[b]呋喃-7-胺 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以73.5 %的产率得到4-bromo-2,3-dihydrobenzofuran-7-amine
  参考文献：
  名称：

  NOVEL THYROID HORMONE ß RECEPTOR AGONIST

  摘要：

  本申请提供具有更好活性、选择性或安全性的新型甲状腺激素β受体激动剂，其由式(I)表示，并用于预防或治疗与β受体激动剂作用相关的疾病。这些疾病包括但不限于肥胖症、高脂血症、高胆固醇血症、糖尿病、肝病(脂肪肝、NASH、NAFLD等)、心血管疾病(动脉粥样硬化等)、甲状腺疾病(甲状腺功能减退症、甲状腺癌等)。

  公开号：

  EP4159723A1
• 作为产物：
  描述：

  2,3-二氢苯并呋喃 在 sodium hydroxide 、 正丁基锂 、 sodium azide 、 四甲基乙二胺 、 三氟乙酸 、 三氟乙酸酐 作用下， 以 甲醇 、 正庚烷 为溶剂， 生成 2,3-二氢苯并[b]呋喃-7-胺
  参考文献：
  名称：

  Synthesis and SAR of highly potent dual 5-HT1A and 5-HT1B antagonists as potential antidepressant drugs

  摘要：

  Novel 5-HT1 autoreceptor ligands based on the N-4-aryl-piperazinyl-N'-ethyl-5,6,7,8-tetrahydropyrido[4', 3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one core are described. Aiming at antidepressants with a novel mode of action our objective was to identify potent antagonists showing balanced affinities and high selectivity for the 5-HT1A and 5-HT1B receptors. Strategies for the development of dual 5-HT1A and 5-HT1B antagonists based on 1 and 2 as leads and the corresponding results are discussed. Isoquinoline analogue 33 displayed high affinity and an antagonistic mode of action for the 5-HT1A and the 5-HT1B receptors and was characterized further with respect to selectivity, electrically stimulated [H-3]5-HT release and in vivo efficacy. (c) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2005.04.077

文献信息

• Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors
  作者：Pei-Tzu Huang、Sirle Saul、Shirit Einav、Christopher R. M. Asquith

  DOI：10.3390/molecules26237338

  日期：——

  Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.

  新兴病毒感染，包括那些由登革热病毒（DENV）和委内瑞拉马脑炎病毒（VEEV）引起的感染，构成了全球重大的健康挑战。在这里，我们报告了针对DENV和VEEV的一系列4-苯胺基喹啉类化合物库的制备和筛选工作。这一努力产生了一系列主导化合物，每个化合物占据着不同的化学空间，包括3-((6-溴喹啉-4-基)氨基)酚（12）、6-溴-N-(5-氟-1H-吲哚-6-基)喹啉-4-胺（50）和6-((6-溴喹啉-4-基)氨基)异吲哚啉-1-酮（52），对DENV感染的EC50值为0.63-0.69 µM。这些化合物库在几乎所有情况下表现出非常有限的毒性，CC50值大于10 µM。此外，主导化合物被筛选用于对抗VEEV，并在低个位数微摩尔范围内展示了活性，其中50和52的EC50分别为2.3 µM和3.6 µM。这里呈现的有希望的结果突显了进一步完善这一系列的潜力，以开发针对DENV、VEEV和潜在其他新兴病毒威胁的临床化合物。
• Fe-Catalyzed Amination of (Hetero)Arenes with a Redox-Active Aminating Reagent under Mild Conditions
  作者：Jianzhong Liu、Kai Wu、Tao Shen、Yujie Liang、Miancheng Zou、Yuchao Zhu、Xinwei Li、Xinyao Li、Ning Jiao

  DOI：10.1002/chem.201605476

  日期：2017.1.12

  A novel and efficient Fe‐catalyzed direct C−H amination (NH2) of arenes is reported using a new redox‐active aminating reagent. The reaction is simple, and can be performed under air, mild, and redox‐neutral conditions. This protocol has a broad substrate scope and could be used in the late‐stage modification of bioactive compounds. Mechanistic studies demonstrate that a radical pathway could be involved

  据报道，使用新型的氧化还原活性胺化试剂，新型有效的铁催化的芳烃直接CH-H胺化（NH 2）。该反应很简单，可以在空气，温和和氧化还原中性条件下进行。该方案具有广泛的底物范围，可用于生物活性化合物的后期修饰。机理研究表明，自由基途径可能参与了这种转化。
• PYRIMIDINE DERIVATIVES
  申请人：Kettle Jason Grant

  公开号：US20110046108A1

  公开（公告）日：2011-02-24

  The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R 1 , ring A, n, R 3 , and R 4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

  这项发明涉及Formula (I)的苯甲酰胺化合物或其药用可接受的盐，其中R1、环A、n、R3和R4如描述中所定义。本发明还涉及制备这种化合物的方法、含有它们的药物组合物以及它们在制造用作抗增殖剂的药物中的用途，用于预防或治疗对EphB4、EphA2和/或Src激酶抑制敏感的肿瘤或其他增殖病症。
• [EN] APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS<br/>[FR] INHIBITEURS DE KINASE 1 DE RÉGULATION DE SIGNAL D'APOPTOSE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009123986A1

  公开（公告）日：2009-10-08

  The present invention relates to apoptosis signal-regulating kinase 1 ("ASK1") inhibiting compounds of the formula (I); wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及具有以下结构的凋亡信号调节激酶1（"ASK1"）抑制化合物（I）；其中变量如本文所定义。该发明还涉及包含这些化合物的药物组合物、试剂盒和制造品；用于制备这些化合物的有用中间体和方法；以及使用这些化合物的方法。
• 2-AMINOQUINOLINE DERIVATIVES
  申请人：Kolczewski Sabine

  公开号：US20080081907A1

  公开（公告）日：2008-04-03

  The present invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein X, Y, Ar 1 , and Ar 2 are as defined in the specification.

  本发明涉及如下式(I)的化合物或其药用可接受的盐，其中X、Y、Ar1和Ar2的定义如规范中所述。